Erik J. Blok

847 total citations
19 papers, 548 citations indexed

About

Erik J. Blok is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Erik J. Blok has authored 19 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Genetics and 8 papers in Cancer Research. Recurrent topics in Erik J. Blok's work include Estrogen and related hormone effects (8 papers), Breast Cancer Treatment Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Erik J. Blok is often cited by papers focused on Estrogen and related hormone effects (8 papers), Breast Cancer Treatment Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Erik J. Blok collaborates with scholars based in Netherlands, United Kingdom and Germany. Erik J. Blok's co-authors include Cornelis J.�H. van de Velde, Judith R. Kroep, Peter J.K. Kuppen, Gerrit‐Jan Liefers, Elma Meershoek‐Klein Kranenbarg, Hein Putter, Cornelis F.M. Sier, J.W.R. Nortier, Emiel J. Rutgers and Marjolijn Duijm‐de Carpentier and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Erik J. Blok

19 papers receiving 542 citations

Peers

Countries citing papers authored by Erik J. Blok

Since Specialization

Citations

This map shows the geographic impact of Erik J. Blok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik J. Blok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik J. Blok more than expected).

Fields of papers citing papers by Erik J. Blok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik J. Blok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik J. Blok. The network helps show where Erik J. Blok may publish in the future.

Co-authorship network of co-authors of Erik J. Blok

This figure shows the co-authorship network connecting the top 25 collaborators of Erik J. Blok. A scholar is included among the top collaborators of Erik J. Blok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik J. Blok. Erik J. Blok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer 2022 ·Oncogene ·(unknown), Begüm Kocatürk, Araci M. R. Rondon, (unknown), (unknown), Rob F. P. van den Akker, Daniëlle Krijgsman, Iris Noordhoek, Erik J. Blok, Vladimir Y. Bogdanov, Wolfram Ruf, Peter J.K. Kuppen, Henri H. Versteeg	15
2	Symptomatic rebound methaemoglobinaemia after treatment with dapsone. 2020 ·The Netherlands Journal of Medicine ·(unknown), (unknown), Erik J. Blok, (unknown), (unknown), (unknown), Andrei N. Tintu, Carina Bethlehem, Jorie Versmissen	1
3	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials 2020 ·Journal of Clinical Oncology ·Iris Noordhoek, Erik J. Blok, Elma Meershoek‐Klein Kranenbarg, Hein Putter, Marjolijn Duijm‐de Carpentier, Emiel J. Rutgers, Caroline Seynaeve, John M.S. Bartlett, Jean-Michel Vannetzel, Daniel Rea, Annette Hasenburg, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, Johanneke E.A. Portielje, Judith R. Kroep, Cornelis J.�H. van de Velde, Gerrit‐Jan Liefers	21
4	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer 2019 ·Molecular Cancer Therapeutics ·Márcia A. Inda, Erik J. Blok, Peter J.K. Kuppen, Ayoub Charehbili, (unknown), (unknown), (unknown), Elma Meershoek‐Klein Kranenbarg, Susan L. Kloet, Bart van der Burg, John W.M. Martens, Andrew H. Sims, Arran Turnbull, J. Michael Dixon, Wim Verhaegh, Judith R. Kroep, Cornelis J.�H. van de Velde, Anja van de Stolpe	39
5	Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy 2019 ·Breast Cancer Research and Treatment ·(unknown), Erik J. Blok, Ayoub Charehbili, C.C. Engels, Vincent T.H.B.M. Smit, (unknown), Hein Putter, Elma Meershoek‐Klein Kranenbarg, Cornelis J.�H. van de Velde, Gerrit‐Jan Liefers, J.W.R. Nortier, Peter J.K. Kuppen, Sjoerd H. van der Burg, Judith R. Kroep	18
6	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes 2019 ·Breast Cancer Research ·Marcelo Sobral‐Leite, (unknown), Mark Opdam, (unknown), Karin Beelen, Vincent van der Noort, Ronald L. P. van Vlierberghe, Erik J. Blok, Daniele Giardiello, Joyce Sanders, Koen Van de Vijver, Hugo M. Horlings, Peter J.K. Kuppen, Sabine C. Linn, Marjanka K. Schmidt, Marleen Kok	82
7	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer 2018 ·European Journal of Cancer ·Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Hein Putter, Gerrit‐Jan Liefers, J.W.R. Nortier, Emiel J. Rutgers, Caroline Seynaeve, Cornelis J.�H. van de Velde	8
8	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer 2018 ·Breast Cancer Research and Treatment ·Erik J. Blok, C.C. Engels, (unknown), Elma Meershoek‐Klein Kranenbarg, Hein Putter, Vincent T.H.B.M. Smit, Gerrit‐Jan Liefers, James P. Morden, Judith M. Bliss, R. Charles Coombes, John M.S. Bartlett, Judith R. Kroep, Cornelis J.�H. van de Velde, Peter J.K. Kuppen	12
9	Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy? 2017 ·European Journal of Cancer ·Marloes Swets, Peter J.K. Kuppen, Erik J. Blok, Hans Gelderblom, Cornelis J.�H. van de Velde, Irıs D. Nagtegaal	18
10	Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe 2017 ·Cancer Treatment Reviews ·Erik J. Blok, Esther Bastiaannet, Wilbert B. van den Hout, Gerrit‐Jan Liefers, Vincent T.H.B.M. Smit, Judith R. Kroep, Cornelis J.�H. van de Velde	51
11	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer 2017 ·Breast Cancer Research and Treatment ·(unknown), Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Hein Putter, Gerrit‐Jan Liefers, J.W.R. Nortier, Emiel J. Rutgers, Caroline Seynaeve, Cornelis J.�H. van de Velde	5
12	Tumor-infiltrating lymphocytes, tumor-associated macrophages and HLA class 1 expression in breast cancer patients treated with neoadjuvant chemotherapy with or without zoledronic acid: A sub study of the NEOZOTAC trial 2017 ·Annals of Oncology ·(unknown), Erik J. Blok, Ayoub Charehbili, C.C. Engels, Vincent T.H.B.M. Smit, (unknown), Hein Putter, Cornelis J.�H. van de Velde, Gerrit‐Jan Liefers, J.W.R. Nortier, Peter J.K. Kuppen, Sjoerd H. van der Burg, Judith R. Kroep	1
13	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial 2017 ·The Lancet Oncology ·Marloes G.M. Derks, Erik J. Blok, Caroline Seynaeve, J.W.R. Nortier, Elma Meershoek‐Klein Kranenbarg, Gerrit‐Jan Liefers, Hein Putter, Judith R. Kroep, Daniel Rea, Annette Hasenburg, Christos Markopoulos, Robert Paridaens, Jan Smeets, Luc Dirix, Cornelis J.�H. van de Velde	38
14	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) 2017 ·JNCI Journal of the National Cancer Institute ·Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, Hein Putter, Jackie Bosch, E. Maartense, A. Elise van Leeuwen‐Stok, Gerrit‐Jan Liefers, J.W.R. Nortier, Emiel J. Rutgers, Cornelis J.�H. van de Velde, (unknown)	122
15	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer 2017 ·Oncotarget ·Erik J. Blok, Jitske van den Bulk, (unknown), Remco Derr, (unknown), Esther Bastiaannet, Judith R. Kroep, Cornelis J.�H. van de Velde, Peter J.K. Kuppen	20
16	Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05) 2017 ·European Journal of Cancer ·C.J.H. Van de Velde, Erik J. Blok, Elma Meershoek‐Klein Kranenbarg, Hein Putter, (unknown), E. Maartense, Marjolijn Duijm‐de Carpentier, Elise van Leeuwen-Stok, Gerrit‐Jan Liefers, (unknown), Emiel J. Rutgers, Judith R. Kroep	6
17	Tumour immune subtyping as a predictive biomarker for adjuvant endocrine therapy in early breast cancer 2016 ·Cancer Research ·Erik J. Blok, C.C. Engels, (unknown), (unknown), Judith R. Kroep, Peter J.K. Kuppen, Cornelis J.�H. van de Velde	1
18	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence 2015 ·Cancer Treatment Reviews ·Erik J. Blok, Marloes G.M. Derks, Jacobus J. M. van der Hoeven, Cornelis J.�H. van de Velde, Judith R. Kroep	25
19	Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer 2013 ·Clinical Medicine Insights Oncology ·Erik J. Blok, Peter J.K. Kuppen, (unknown), Cornelis F.M. Sier	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact